
FIG. 1


Protege; Herold Regimen
Encore; Herold Regimen
Protege; Regimen 1
Encore; Regimen 1
Protege; Herold Regimen 2
Encore; Herold Regimen 2
Protege; Regimen 1
Encore; Regimen 2
Protege; Herold
Protege; Regimen1
Concentration (ng/mL)
Time (days)
Time after last dose (days)



Regimen 1: Median
Regimen 2: Median
Regimen 1: 90% Prediction Interval
Regimen 2: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
Time (days)
0
5
10
15

FIG. 2



Regimen 1: Median
Herold: Median
Regimen 1: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
Time (days)
0
5
10
15

FIG. 3




Regimen 1: Median
Herold: Median
Regimen 1: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
0.0
0.2
0.4
0.6
0.8
1.0
Time after dose (days)

FIG. 4

FIG. 5


Protege; Herold Regimen
Encore; Herold Regimen
Protege; Regimen 1
Encore; Regimen 1
Protege; Herold Regimen 2
Encore; Herold Regimen 2
Protege; Regimen 1
Encore; Regimen 2
Protege; Herold
Protege; Regimen1
Concentration (ng/mL)
Time (days)
Time after last dose (days)



Regimen 1: Median
Regimen 2: Median
Regimen 1: 90% Prediction Interval
Regimen 2: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
Time (days)
0
5
10
15

FIG. 6



Regimen 1: Median
Herold: Median
Regimen 1: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
Time (days)
0
5
10
15

FIG. 7




Regimen 1: Median
Herold: Median
Regimen 1: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
0.0
0.2
0.4
0.6
0.8
1.0
Time after dose (days)

FIG. 8

FIG. 9


Protege; Herold Regimen
Encore; Herold Regimen
Protege; Regimen 1
Encore; Regimen 1
Protege; Herold Regimen 2
Encore; Herold Regimen 2
Protege; Regimen 1
Encore; Regimen 2
Protege; Herold
Protege; Regimen1
Protege; Herold
Protege; Regimen1
Concentration (ng/mL)
Time (days)
Time after last dose (days)



Regimen 1: Median
Regimen 2: Median
Regimen 1: 90% Prediction Interval
Regimen 2: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
Time (days)
0
5
10
15

FIG. 10



Regimen 1: Median
Herold: Median
Regimen 1: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
Time (days)
0
5
10
15

FIG. 11




Regimen 1: Median
Herold: Median
Regimen 1: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
0.0
0.2
0.4
0.6
0.8
1.0
Time after dose (days)

FIG. 12

FIG. 13


Protege; Herold Regimen
Encore; Herold Regimen
Protege; Regimen 1
Encore; Regimen 1
Protege; Herold Regimen 2
Encore; Herold Regimen 2
Protege; Regimen 1
Encore; Regimen 2
Protege; Herold
Protege; Regimen1
Protege; Herold
Protege; Regimen1
Concentration (ng/mL)
Time (days)
Time after last dose (days)



Regimen 1: Median
Regimen 2: Median
Regimen 1: 90% Prediction Interval
Regimen 2: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
Time (days)
0
5
10
15

FIG. 14



Regimen 1: Median
Herold: Median
Regimen 1: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
Time (days)
0
5
10
15

FIG. 15



Regimen 1: Median
Herold: Median
Regimen 1: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
1400
0.0
0.2
0.4
0.6
0.8
1.0
Time after dose (days)

FIG. 16



Regimen 2: Median
Herold: Median
Regimen 2: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
Time (days)
0
10
20
30
40

FIG. 17



Median Regimen 2
Median Herold
Concentration (ng/mL)
0
200
400
600
800
Time (days)
0
5
10
15
20
25
30
35

FIG. 18



Regimen 2: Median
Herold: Median
Regimen 2: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
Time (days)
0
10
20
30
40

FIG. 19



Median Regimen 2
Median Herold
Concentration (ng/mL)
0
200
400
600
800
Time (days)
0
5
10
15
20
25
30
35

FIG. 20



Regimen 2: Median
Herold: Median
Regimen 2: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
Time (days)
0
10
20
30
40

FIG. 21



Median Regimen 2
Median Herold
Concentration (ng/mL)
0
200
400
600
800
Time (days)
0
5
10
15
20
25
30
35

FIG. 22



Regimen 2: Median
Herold: Median
Regimen 2: 90% Prediction Interval
Herold: 90% Prediction Interval
Concentration (ng/mL)
0
200
400
600
800
1000
1200
Time (days)
0
10
20
30
40

FIG. 23



Median Regimen 2
Median Herold
Concentration (ng/mL)
0
200
400
600
800
Time (days)
0
5
10
15
20
25
30
35

FIG. 24

FIG. 25



Randomization:
2:1; Active:Placebo
N= 300 (200A; 100P)
Stratification:
Age: ≤ vs. > 12 years old
2h MMTT Peak C-peptide: ≤ vs. > 0.7 pmol/mL
R
Teplizumab Dose/Course = 9.0 mg/m²
Day 1: 106 µg/m² IV
Day 2: 425 µg/m² IV
Days 3-12: 850 µg/m² IV
Placebo
T1D AA Screen
Treatment Phase
Off Treatment Observation Phase
Week: -6 0 26 52 78
Treatment: C1 D1-12 C2 D182-193
MMTT: 2h 4h 4h 4h 4h
Endpoint: Baseline C/M C/M 1° EP C/M
R = Randomization; = Optional Pre-Screen of T1D AAs; C1 = Course 1; C2 = Course 2; = Key Clinical/Metabolic Endpoint; = 1° Endpoint = Δ C-peptide AUC

FIG. 26

	N		LSM Difference Between Teplizumab and Control in Change from Baseline	LSM (95% CI)
	Teplizumab	Control		
Overall Observed	**306**	**179**		**0.08** (0.04, 0.12)
Overall Imputed	**375**	**234**		**0.09** (0.05, 0.13)
Protégé Observed	**188**	**91**		**0.04** (-0.002, 0.08)
Protégé Imputed	**207**	**98**		**0.03** (-0.01, 0.08)
Encore Observed	**17**	**17**		**0.002** (-0.11, 0.12)
Encore Imputed	**63**	**62**		**0.05** (-0.06, 0.15)
AbATE Observed	**50**	**22**		**0.15** (0.06, 0.23)
AbATE Imputed	**52**	**35**		**0.15** (0.06, 0.24)
Delay Observed	**30**	**28**		**0.06** (-0.03, 0.15)
Delay Imputed	**32**	**28**		**0.06** (-0.03, 0.15)
Study 1 Observed	**21**	**21**		**0.16** (0.05, 0.26)
Study 1 Imputed	**21**	**21**		**0.16** (0.05, 0.26)

Note: Analysis conducted and results presented for ln(AUC+1)
Abbreviations: AUC=area under the concentration-time curve, CI=confidence interval, LSM=least squares mean
N=number with 1-year data included in the meta-analysis

FIG. 27

	N		LSM Difference Between Teplizumab and Control in Change from Baseline	LSM (95% CI)
	Teplizumab	Control		
Observed	199	99		**0.12** (0.07, 0.17)
Imputed	280	144		**0.10** (0.05, 0.16)
Protégé Observed	131	64		**0.06** (0.004, 0.11)
Protégé Imputed	207	98		**0.06** (0.01, 0.10)
AbATE Observed	49	21		**0.14** (0.05, 0.23)
AbATE Imputed	52	25		**0.14** (0.05, 0.23)
Study 1 Observed	19	14		**0.16** (0.04, 0.28)
Study 1 Imputed	21	21		**0.12** (0.001, 0.24)

Note: Analysis conducted and results presented for ln(AUC+1)
AUC=area under the concentration-time curve, CI=confidence interval, LSM=least squares mean, N=number with 2-year data included in the meta-analysis



AUC 2-H-OGTT
3
2.5
2
1.5
Teplizumab
Placebo
0 3 6 12 18 24 30 36 42 48 54 60 66
Analysis Visit (months)
Number of Patients with all 3 tests available
Teplizumab 20 18 20 18 15 9 8 5 5
Placebo 23 22 15 11 9 8 7

FIG. 28

FIG. 29



a. Protégé
Placebo
Teplizumab
Average insulin use (U/kg/day)
0.7
0.65
0.6
0.55
0.5
Baseline
91
140
273
364
448
546
616
728
Day
Number of Patients at Risk
Teplizumab 205 199 199 186 185 176 179 163 171
Placebo 96 97 94 89 93 88 85 88 88

FIG. 29 (cont.)

b. Encore




FIG. 29 (cont.)

c. Study 1




FIG. 29 (cont.)

d. AbATE





FIG. 29 (cont.)

e. Delay






Cycle 1: Typical 40 and 90 kg male subject
Concentration (ng/mL)
0
200
400
600
800
Time (days)
0
5
10
15
20
Cycle 1: Typical 60 kg male subject
Concentration (ng/mL)
0
200
400
600
800
Time (days)
0
5
10
15
20

FIG. 30

FIG. 31


Plot Emax model - Predicted C-peptide change (95% CI) vs AUC, Year 2 - Year 2, All Active Groups - Protege
Change from Baseline
0.25
0.00
-0.25
-0.50
-0.75
1500
AGC Bio AUC
(min 1789, median 3277, max 7684 ng*hr/mL)
0
2000
4000
6000
8000
10000
AUC
Actual Treatment for Period 01
Teplizumab Full Regimen
Teplizumab 1/3 Regimen
Teplizumab Curtailed Regimen